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Introduction: Primary Sjögren’s syndrome (pSS) is an autoimmune disorder affecting exocrine glands; however, a
subgroup of pSS patients experience systemic extra-glandular involvement leading to a worsening of disease prog-
nosis. Current therapeutic options are mainly empiric and often translated by other autoimmune diseases. In the last
few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS. Patients with
early active disease appear to be those who could benefit the most from RTX. The aim of this study was to investi-
gate the efficacy and safety of RTX in comparison to disease modifying anti-rheumatic drugs (DMARDs) in early
active pSS patients.
Methods: Forty-one patients with early pSS and active disease (EULAR Sjogren’s syndrome disease activity index,
ESSDAI ≥ 6) were enrolled in the study. Patients were treated with either RTX or DMARDs in two different
Rheumatology centers and followed up for 120 weeks. Clinical assessment was performed by ESSDAI every
12 weeks up to week 120 and by self-reported global disease activity pain, sicca symptoms and fatigue on visual
analogic scales, unstimulated saliva flow and Schirmer’s I test at week 12, 24, 48, 72, 96, and 120. Laboratory
assessment was performed every 12 weeks to week 120. Two labial minor salivary gland (MSG) biopsies were
obtained from all patients at the time of inclusion in the study and at week 120.
Results: Our study demonstrated that RTX treatment results in a faster and more pronounced decrease of ESSDAI
and other clinical parameters compared to DMARDs treatment. No adverse events were reported in the two
groups. We also observed that RTX is able to reduce glandular infiltrate, interfere with B/T compartmentalization
and consequently with the formation of ectopic lymphoid structures and germinal center-like structures in
pSS-MSGs.
Conclusions: To our knowledge, this is the first study performed in a large cohort of early active pSS patients for a
period of 120 weeks. We showed that RTX is a safe and effective agent to be employed in pSS patients with
systemic, extra-glandular involvement. Furthermore, our data on pSS-MSGs provide additional biological basis to
employ RTX in this disease.* Correspondence: francescocarubbi@libero.it
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Primary Sjögren’s syndrome (pSS) is a systemic auto-
immune disease characterized by mucosal dryness in the
majority of patients. General symptoms of pSS include
fatigue, weight loss and fever [1,2], and extraglandular
manifestations occur in 20 to 40% of patients affecting
the musculoskeletal system, skin, peripheral and central
nervous system, kidneys, lungs [3] and health-related
quality of life (HR-QoL) [4].
Classically, minor salivary glands (MSGs) of patients
with pSS show a focal lymphocytic sialadenitis (FLS)
characterized by the presence of one or more dense
aggregates of 50 or more lymphocytes usually located in
perivascular or periductal areas. The infiltrating lympho-
cytes are often organized into tertiary lymphoid tissues
in nonlymphoid locations, also known as ectopic lymph-
oid structures showing a network including specific seg-
regated T-cell and B-cell zones and follicular dendritic
cells. Some of these tertiary lymphoid tissues are arranged
in germinal centers (GC) [5,6].
Concerning pSS pathogenesis, B-lymphocyte hyperactiv-
ity, MSG infiltration and development of B-cell follicles
containing GC-like structures represent the hallmarks of
the disease. Although the peculiar role of B cells in auto-
immunity is the production of autoantibodies, growing
evidence suggest that B cells may also exert additional piv-
otal functions such as antigen presentation and release of
specific cytokines with immune regulatory, proinflamma-
tory, polarizing and tissue-organizing functions [7,8].
Prolonged B-cell survival and aberrant B-cell activity
may lead to the development of non-Hodgkin lymph-
omas in 5% of pSS patients, and among these extranodal
marginal zone B-cell lymphoma of the mucosa-associated
lymphoid tissue represents the most common subtype
[9]. Strong predictors of lymphoproliferative disorder
in pSS include parotid, lymph node and/or splenic
enlargement, monoclonal gammopathy, hypogamma-
globulinemia, mixed cryoglobulinemia, palpable pur-
pura, CD4+ T-cell lymphopenia and/or reduced levels
of C4 [10].
B-cell activating factor (BAFF), also named B-lymphocyte
stimulator, is an important member of the tumor necrosis
factor family and is involved in B-cell survival and humoral
immune responses, playing a critical role in B-cell homeo-
stasis [11]. BAFF overexpression rescues autoreactive cells
from depletion in periphery, leading to a higher number of
mature autoreactive B cells [12]. Patients with pSS display
elevated levels of BAFF in serum, saliva and salivary glands
[13-15]. In their sera, BAFF levels correlate with gamma-
globulin levels, anti-SSA and/or anti-SSB antibodies. Fur-
thermore, higher BAFF levels are observed in patients with
GCs in salivary glands [16,17]. Evidence from animal
models and patients with pSS demonstrated that the for-
mation and maintenance of tertiary lymphoid tissues iscritically dependent on ectopic expression of lymphotoxins
and homeostatic chemokines such as CXCL13 and
CXCL12 and interaction with their specific receptors,
CXCR5 and CXCR4 respectively. These key molecules are
produced during chronic inflammation by several cell types,
including resident epithelial, stromal and endothelial cells,
as well as different subsets of infiltrating immune cells [18].
Moreover, such lymphoid chemokines exert a critical role
during lymphoid organogenesis, allow the transformation
of diffuse infiltrates into highly organized structures that are
necessary for the initiation of the adaptive immune re-
sponse, and, as already mentioned, play an important role
in tertiary lymphoid tissue development [19].
The lymphotoxin-alpha (LTα) and lymphotoxin-beta
(LTβ) pathways have been associated with the presence
of ectopic lymphoid structures at the sites of chronic
inflammation in several autoimmune diseases [20]. Fur-
thermore, when compared with the inflammatory process
of nonspecific sialoadenitis, salivary glands of patients with
pSS have been found to express a unique profile of adhe-
sion molecules, cytokines and chemokines, including a
striking overexpression of CXCL13 and, to a lesser degree,
CXCL12 [5,21-23]. B cells expressing the corresponding
receptors for CXCL13 and CXCL12 have been detected in
the peripheral blood and glandular infiltrates of pSS
patients [24,25]. The striking glandular overexpression of
CXCL12 and CXCL13 in pSS patients might contribute to
the preferential migration of CXCR4 and CXCR5 express-
ing CD27+ memory B cells into the inflamed salivary
glands, resulting in lower numbers of circulating CD27+
memory cells [24]. Furthermore, CXCL12–CXCR4 and
CXCL13–CXCR5 interactions have been widely suggested
to be involved in B-cell disturbance during pSS and
may be closely associated with the whole inflammatory
process, the development of ectopic GC-like structures as
well as the peripheral B-cell abnormalities [25].
Treatment of pSS is largely empiric and in the last
50 years has been mainly symptomatic. In this setting,
systematic reviews highlighted the limited evidence
available for the drugs that are frequently used in pSS
and the difficulties in elaborating solid therapeutic rec-
ommendations [26]. The increasing availability of tar-
geted therapies in the last two decades, mirroring what
happened in rheumatoid arthritis, raised the possibility
in pSS to selectively interfere with different pathogenic
pathways. On this basis, B-cell depletion by rituximab
(RTX) represents an issue of great interest. RTX is a
chimeric humanized monoclonal anti-CD20 antibody.
CD20 is expressed on the surface of pre-B lymphocytes,
transitional B lymphocytes and mature B lymphocytes,
and is lost at the plasma cell stage [27]. CD20 mediates
B-cell activation, proliferation and differentiation [28]
and plays an important role in the generation of T-cell-
independent antibody responses [29].
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evidence from both open-label studies and randomized
clinical trials provide the clue that RTX is effective in re-
ducing various disease manifestations of pSS patients,
such as sicca symptoms, extraglandular manifestations
and fatigue, and in improving saliva production and,
where explored, HR-QoL [28,30,31]. Following B-cell de-
pletion therapy by RTX, an increase in serum levels of
BAFF was observed in pSS; and to note, higher baseline
serum levels of BAFF resulted in a shorter duration of
B-cell depletion by RTX, indicating a role of BAFF in
the repopulation of B cells after RTX treatment [32,33].
Regarding the effect of RTX therapy on the levels of
LTα, LTβ and the chemokine–chemokine receptor pairs
CXCL13–CXCR5 and CXCL12–CXCR4, in patients
affected by pSS, no data are currently available in the
literature. Studies reporting the effects of RTX treatment
in rheumatoid arthritis, multiple sclerosis and B-cell
malignancies allow one to speculate that similar effects
could occur during pSS. In particular, serum levels of
CXCL13 were found to be predictive for the repopulation,
following a single course of RTX in rheumatoid arthritis.
A direct correlation between serum and synovial CXCL13
was also observed in these patients [34].
Although B-cell-depleting therapy with RTX provided
promising results, the underlying mechanisms of action
are not completely understood and, it is still unclear why
some pSS patients fail to achieve a good clinical response.
In this setting, one must point out that patients with re-
sidual salivary function and treated in early phases of the
disease showed a better response concerning eye dryness,
fatigue and HR-QoL [35,36]. Consistent clinical improve-
ment was also reported for both glandular enlargement
[37] and extraglandular manifestations [31,36,38-40]. On
this basis, we can speculate that pSS patients with early,
active disease, experiencing extraglandular manifestations,
might strongly benefit from RTX treatment.
The aim of this prospective, multi-center, follow-up study
was to assess the safety and efficacy of RTX, compared
with treatment with disease-modifying anti-rheumatic
drugs (DMARDs), in recent-onset pSS patients, with
active disease, by a follow-up period of 120 weeks. MSG
biopsy was employed in the study both to confirm the
diagnosis of pSS and to evaluate histological and molecu-
lar modification in the tissues, following treatment. Clin-
ical response was evaluated by validated measures.
Methods
Study population
Forty-one consecutive patients referring to the Rheumatology
Unit, University of L’Aquila, Italy, or to the Rheumatology
Unit, University of Palermo, Italy, were enrolled. All pa-
tients were over 18 years old and fulfilled the American–
European consensus criteria for pSS, including histopathologiccriteria [41]. Inclusion criteria were: pSS diagnosis, recent
onset of the disease (maximum 2 years from the onset of
first symptoms related to the disease) and active disease,
as defined by values >50 mm for two out four visual ana-
logical scales (VAS; 0 to 100 mm) such as: global disease
activity (including extraglandular manifestations); pain;
sicca symptoms; and fatigue, and a EULAR Sjögren’s syn-
drome disease activity index (ESSDAI) [42] arbitrarily
chosen ≥6. Patients were excluded for secondary Sjögren’s
syndrome, severe cardiac, pulmonary, renal or hematologic
failure, a history of cancer in the last 5 years, hepatitis
B or hepatitis C infection, human immunodeficiency virus
infection, tuberculosis, severe diabetes, and any other
chronic disease, or evidence of infection, and if they were
unable to understand and to adhere to the protocol.
Treatment with DMARDs and corticosteroids was discon-
tinued at least 6 months before baseline, except for these
patients with severe extraglandular manifestations needing
continuation of treatment (with no change in dosage
allowed). The use of any systemic drug for the relief of
dryness-related symptoms was not allowed during the
study.
Study design and sample size
This is a prospective, multi-center, follow-up study. The
whole study was approved by the local ethics committee
of the study coordinator (Local Health Authority ASL 1
Avezzano-Sulmona-L’Aquila Ethic Committee) and per-
formed according to the Good Clinical Practice guidelines.
All patients provided written informed consent in accord-
ance with the declaration of Helsinki. Patients enrolled by
the Rheumatology Unit of L’Aquila received RTX therapy
with a stable dose of prednisone (RTX arm, 19 patients)
and patients enrolled by the Rheumatology Unit of
Palermo were treated with one or more DMARDs (hydro-
xychloroquine, methotrexate, cyclosporine) that are largely
used in this disease, although no one of these has been
licensed for pSS, in association with a stable dose of pred-
nisone (DMARD arm, 22 patients), according to clinical
manifestations. Based on a formal sample size calculation,
41 patients were included, of whom 19 were assigned to
receive RTX and 22 to receive DMARD treatment. The
duration of the study was 120 weeks.
Rituximab administration
Patients in the RTX arm received infusion of 1,000 mg
rituximab (Mabthera®; F. Hoffmann-La Roche AG, Basel,
Switzerland) at day 1 and at day 15 to complete a course
of therapy. This course was repeated every 24 weeks.
During the study period, all patients received six courses
of therapy with RTX. To minimize side effects, all pa-
tients were pretreated with methylprednisolone (40 mg
intravenously), paracetamol (1,000 mg orally) and chlor-
pheniramine (10 mg intravenously).
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The primary endpoints of this study were: the evaluation
of the safety of RTX infusion; and a significant variation
in the reduction of the ESSDAI in the RTX arm during
the study period. Secondary endpoints were measure-
ments of salivary/lacrimal function, subjective variables
and biologic effects of RTX in MSGs, compared with pa-
tients treated with DMARD therapy.
Clinical assessment
The disease activity was assessed using the ESSDAI at
baseline and every 12 weeks to week 120. The following
self-reported outcomes on VAS (0 to 100 mm), evaluated
at baseline and weeks 12, 24, 48, 72, 96, and 120, were
employed: global disease activity (including extraglandular
manifestations), pain, sicca symptoms and fatigue. An in-
dependent blind clinician provided the degree of physician
global assessment of the disease activity by VAS, evaluated
at baseline and weeks 12, 24, 48, 72, 96, and 120. Unstimu-
lated saliva flow and Schirmer’s I test for ocular function
were performed at baseline and weeks 12, 24, 48, 72, 96,
and 120, as described previously [43,44]. The IgG concen-
tration, antinuclear antibodies, anti-Ro/SSA and anti-La/
SSB antibodies, and rheumatoid factor were also assessed
at baseline and weeks 12, 24, 48, 72, 96, and 120.
Histological analysis of minor salivary gland biopsies
Two labial MSG biopsies were obtained from all patients
at the time of inclusion in the study and at week 120. Five
healthy donors (four women and one man) with sicca
symptoms but normal MSGs and absence of any clinical
and serological feature of Sjögren’s syndrome acted as
controls. These samples were divided into two parts: the
first for histologic analysis, and the second for RNA isola-
tion and quantitative real-time polymerase chain reaction.
For histologic evaluation, hematoxylin–eosin-stained sec-
tions were examined by a blinded, trained operator. We
performed both the Chisholm and Mason score (grades 1
to 4) [45] and the focus score, the latter assessing the
number of foci/4 mm2 (a focus is defined as an aggre-
gate >50 mononuclear cells) [46]. The cellular infiltrate
and the lymphoid organization were assessed by immuno-
fluorescence staining of sequential sections with mono-
clonal antibodies recognizing CD3, CD20, CD21 (all
provided by Dako Cytomation, Glostrup, Denmark),
CXCR4, CXCL12, CXCR5, and CXCR13 (all provided by
R&D System, Abingdon, UK). Formalin-fixed, paraffin-
embedded sections measuring 3 μm in thickness were
dewaxed and rehydrated. All sections underwent high-
temperature antigen retrieval using Target Retrieval Solu-
tion (Dako, Glostrup, Denmark) for 35 minutes at 95°C,
except for sections stained with anti-CD21 that underwent
proteolytic digestion for 7 minutes at 37°C using protein-
ase K (Dako).For sections stained with anti-CD3, anti-CD21, anti-CXCR5
or anti-CXCL12 antibodies, we performed nonspecific binding
blocking (protein block serum-free ready-to-use; Dako).
For sections stained with anti-CD20, anti-CXCR4 or
CXCL13 antibodies, we also performed endogenous bio-
tin blocking (avidin–biotin blocking system; Vector
Laboratories, Burlingame, CA, USA).
To assess T-cell/B-cell segregation, sections were double-
stained with anti-CD3/anti-CD20 antibodies. Monoclonal
mouse anti-human CD3 (dilution 1:50) was incubated for
1 hour at room temperature in a wet chamber, followed
by 30 minutes incubation with secondary antibody goat
anti-mouse/AlexaFluor-555 (1:100; Invitrogen, Paisley,
UK). Subsequently, monoclonal mouse anti-human CD20
(1:20) incubation was performed for 1 hour at room
temperature in a wet chamber, followed by 30 minutes
incubation with biotin goat anti-mouse IgG (1:100;
Biolegend, San Diego, CA, USA) and 30 minutes incuba-
tion with streptavidin/AlexaFluor-488 (1:200; Invitrogen).
To detect follicular dendritic cell networks and iden-
tify GCs, sections were incubated overnight at 4°C with
monoclonal mouse anti-human CD21 (1:20) followed by
30 minutes incubation with secondary antibody goat
anti-mouse/AlexaFluor-488 (1:100; Invitrogen).
To assess the presence of CXCR4 in MSGs, sections
were stained with anti-CXCR4 antibody. Monoclonal
mouse anti-human CXCR4 (dilution 1:50) was incubated
for 1 hour at room temperature in a wet chamber, followed
by 30 minutes incubation with biotin antibody goat anti-
mouse IgG (1:100; Biolegend) and 30 minutes incubation
with streptavidin/AlexaFluor-488 (1:200; Invitrogen).
CXCL12 positivity was evaluated by a specific anti-
CXCL12 antibody. Monoclonal mouse anti-human CXCL12
(1:20) incubation was performed overnight at 4°C in a
wet chamber, followed by 30 minutes incubation with sec-
ondary antibody goat anti-mouse/AlexaFluor-555 (1:100;
Invitrogen).
Anti-CXCR5 antibody was employed to assess the evi-
dence of CXCR5 in the studied samples, which were
incubated with monoclonal mouse anti-human CXCR5
(dilution 1:50) overnight at 4°C in a wet chamber, followed
by 30 minutes incubation with secondary antibody goat
anti-mouse/AlexaFluor-555 (1:100; Invitrogen).
Anti-CXCL13 antibody was employed to assess the
evidence of CXCL13 in the studied samples, which were
incubated with monoclonal mouse anti-human CXCL13
(dilution 1:50) for 1 hour at room temperature in a wet
chamber, followed by 30 minutes incubation with biotin
antibody goat anti-mouse IgG (1:100; Biolegend) and
30 minutes incubation with streptavidin/AlexaFluor-555
(1:200; Invitrogen).
All sections were counterstained with 4′, 6-diamidino-2-
phenylindole (1:1,000) for 10 minutes and slides were
mounted with Mowiol 4–88 (Sigma-Aldrich, Milan, Italy).
Table 1 Demographic, clinical and histological
characteristics of the patient cohort
Treatment group
DMARDs RTX
Number of patients 22 19
Age (years) 43 (30 to 56) 40 (27 to 53)
Sex (female) 22 (100%) 18 (94.7%)
Disease duration (months) 14 (7 to 21) 13 (6 to 20)
Parotid gland enlargement 18 (81.8%) 16 (84.2%)
Cutaneous vasculitis 2 (9.0%) 3 (15.7%)
Pulmonary involvement 1 (4.5%) 1 (5.2%)
Neurological involvement 3 (13.6%) 2 (10.5%)
Renal involvement 0 (0%) 0 (0%)
Autoimmune cytopenia 7 (31.8%) 8 (42.1%)
Myositis 0 (0%) 0 (0%)
Arthritis. 11 (50%) 9 (47.3%)
Lymphadenopathy 15 (68.1%) 17 (89.4%)
ESSDAI 19.8 (6 to 41) 20.3 (6 to 41)
Prednisonea 22 (12.5) 19 (12.5)
DMARDs (HCQ/MTX/CsA) 22 (15/13/8) 0 (0/0/0)
Chisholm and Mason score ≥3 22 19
Focus score 1.8 (1 to 3.3) 1.8 (1 to 3.4)
Data presented as mean (range) or number (%) unless otherwise stated. CsA,
cyclosporine; DMARDs, disease-modifying anti-rheumatic drugs; HCQ,
hydroxychloroquine; MTX, methotrexate; RTX, rituximab. aData presented as
number of patients (mean dose in milligrams).
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cence microscope with CellSens software (Olympus America
Inc., Center Valley, PA, USA). The number of CXCR4-
positive and CXCR5-positive cells was determined as
follows: three random high-power microscopic fields
for each area, showing an immune-inflammatory infil-
trate, were selected and the numbers of CXCR4 and
CXCR5 immunoreactive cells were counted at 200× mag-
nification. The mean values of positive cells in each area
were added and divided for the number of areas in the
section [47].
RNA isolation and quantitative real-time polymerase
chain reaction
Total RNA was extracted from MSGs using TRIZOL
(SIGMA, St. Louis, MO, USA) and reverse transcribed
into complementary DNA (cDNA) with the ThermoScript
reverse transcription–polymerase chain reaction system
(Invitrogen, Carlsbad, CA, USA). The quantitative real-
time polymerase chain reaction was performed using
SYBR green kits and Taqman gene expression assays
(Applied Biosystems, Utrecht, the Netherlands). Results
were analyzed after 40 cycles of amplification using the
ABI 7500 Fast Real Time PCR System (Applied Bio-
systems, Utrecht, the Netherlands). Primers were de-
signed on the basis of the reported sequences (Primer
bank NCBI): LTα, 5′-ATGACACCACCTGAACGTCT
C-3′ (forward) and 5′-CTCTCCAGAGCAGTGAGTTCT-3′
(reverse); LTβ, 5′-GACGAAGGAACAGGCGTTTCT-3′ (for-
ward) and 5′-GTAGCCGACGAGACAGTAGAG-3′ (reverse);
β-actin, 5′-CCTGGCACCCAGCACAAT-3′ (forward) and
5′-AGTACTCCGTGTGGATCGGC-3′ (reverse); CXCR5,




CR4, 5′-GACTTGTGGGTGGTTGTG-3′ (forward) and
5′-AGGATGAGGATGACTGTGG-3′ (reverse); CXCL12,
5′-GAGCCAACGTCAAGCATCTC-3′ (forward) and 5′-




SPSS 13.0 software (IBM, Armonk, NY, USA) was used for
statistical analysis. One-way analysis of variance and mul-
tiple comparison post-hoc tests were employed to calculate
differences between baseline and the following time
points. Differences between the two treatment arms
were tested with nonparametric Mann–Whitney U test.
The Wilcoxon matched-pairs test was used to compare
variables at baseline and week 120. When required, the
chi-square test was also employed. P <0.05 was considered
significant.Results
Baseline demographic and clinical characteristics
Demographic and clinical characteristics of the patients
at baseline were balanced across the RTX and DMARD
groups (Table 1). The mean age of the patients in
DMARD group was 43 years and in the RTX group was
40 years, while the mean disease duration was 14 and
13 months in the DMARD and RTX groups, respect-
ively. The mean ESSDAI score at baseline was 19.8 in
the DMARD group and 20.3 in the RTX group, with an
equal proportion of patients with similar clinical features
in each group.
Primary endpoints
Our study clearly shows that RTX treatment, already from
the second course of therapy, displayed a stronger and
significant effect in decreasing the ESSDAI, when com-
pared with the DMARD arm, and this effect was observed
throughout the study period (Figure 1 and Table 2). Mean
change of ESSDAI from baseline to week 24 was sig-
nificantly greater with RTX than with DMARD therapy
(Table 2). Mean values for ESSDAI were similar at base-
line and decreased sharply by week 12 in both groups.
Thereafter, the ESSDAI response curves separated from
week 24 (Figure 1).
Figure 1 Primary endpoint of the study EULAR Sjögren’s
syndrome disease activity index in the rituximab and disease-
modifying anti-rheumatic drug treatment groups. Primary
endpoint of the study EULAR Sjögren’s syndrome disease activity
index (ESSDAI) in the rituximab (RTX) and the disease-modifying
anti-rheumatic drug (DMARD) treatment groups. Bars in the line
charts indicate mean ± standard error of the mean. *P < 0.05,
comparison between the two treatment arms at the corresponding
time point.
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ported during the study. The RTX infusions were gener-
ally well tolerated in this study and no local or systemic
infusion reactions were observed. No adverse events
judged by the investigator to be possibly, probably, or
definitely related to RTX therapy were observed in the
120-week follow-up period. No patient needed dose
modification or interruption because of adverse events,
and no patients withdrew from the study.
Clinical assessment
The response curves for VAS global disease activity, VAS
pain and physician global assessment showed much the
same pattern of ESSDAI (Figure 2A,B,E and Table 2). In
fact, these items significantly decreased in both groups,
and again the RTX arm showed a better performance
when compared with the DMARD population. Such de-
crease was progressive up to week 72 and then reached
a plateau until week 120.
As far as VAS dryness was concerned, we observed in
the RTX treatment group a progressive improvement of
its score from baseline to week 120 (Figure 2D). On the
contrary, only a slight decrease in VAS dryness was ob-
served in the DMARD treatment group until week 12,
but no further amelioration were detected thereafter. The
results concerning VAS fatigue mirrored those observed
for VAS dryness (Figure 2C). As far as the objective mea-
surements of salivary and lacrimal gland function were
concerned, we observed that both the unstimulated saliv-
ary flow and the Schirmer’s I test were not affected inthe DMARD treatment group (Figure 2F,G and Table 2).
On the contrary, RTX was able to significantly increase
both tests from week 12. Concerning serological parame-
ters, we did not observe any significant difference in IgG
concentration, antinuclear antibodies, rheumatoid factor
and anti-Ro/SSA and anti-La/SSB antibodies in each arm
at any time point and between the two studied groups, be-
fore and after treatment (data not shown).
Histological analysis of minor salivary gland biopsies
At baseline, no significant difference in terms of focus
score and Chisholm and Mason grading were observed be-
tween RTX-treated and DMARD-treated patients (Table 1).
Twelve out of 22 patients in the DMARD group (54.5%)
and 10 out of 19 patients in the RTX group (52.6%) dis-
played GC-like structures at baseline. As summarized in
Figure 3A,B, both Chisholm and Mason grading and focus
score were not modified at week 120 in patients treated
with DMARDs while a significant reduction compared
with baseline was observed in RTX-treated patients. In
particular, in 17 out of 19 RTX-treated patients (89.4%) the
foci number at week 120 was below 1, suggesting that
RTX treatment might reverse the FLS, which is generally
considered specific for pSS, to a nonspecific chronic siala-
denitis pattern or, alternatively, leading to a full restoration
of MSG architecture (Figure 4). Furthermore, we observed
that the number of GC-positive biopsies dropped from
52.6% to 5.2% in RTX-treated patients, and after 30 months
only one out of 19 patients still displayed GCs. On the
contrary, no significance difference were observed in the
DMARD group, where the number of GC-positive biopsies
after treatment was slightly reduced (38.5%) and conver-
sion from a FLS to a nonspecific chronic sialadenitis pat-
tern was rarely observed (Figure 3E).
We also observed a reduction of CXCR4-positive and
CXCR5-positive cell percentage in total infiltrating mono-
nuclear cells when compared with baseline in RTX-treated
patients but not in those treated with DMARDs at week
120 (Figure 3C,D). Figures 3 and 4 display a comparison
between the two treatment arms for the aforementioned
variables.
Molecular analysis of minor salivary gland biopsies
To further support histological findings, we performed
molecular analysis on the same biopsy specimens at
baseline and week 120. Five normal MSGs of subjects
with sicca symptoms and an absence of any clinical and
serological feature of pSS were used as controls. At base-
line, all of the patients, independent of treatment arm,
displayed the same cytokine and chemokine patterns,
which significantly differed from those observed in the
MSGs of the subjects affected by sicca symptoms but
without any feature of immune activation (Figure 5). As
shown in Figure 5A,B, RTX treatment led to a significant
Table 2 Clinical assessment result changes from baseline to week 120 in the rituximab and DMARD treatment groups
BASELINE Week 12 Week 24 Week 48 Week 72 Week 96 Week 120
DMARDs RTX DMARDs RTX DMARDs RTX DMARDs RTX DMARDs RTX DMARDs RTX DMARDs RTX
Global disease activity
VAS (mm)
88.7 ± 3.3 88.7 ± 3.3 77 ± 2.2† 72.4 ± 4.0‡ 71 ± 3.2‡ 68.5 ± 4.6‡ 63 ± 3.9* 60.0 ± 4.6* 54 ± 3.5* 51.8 ± 3.0* 50.5 ± 3.7* 47.1 ± 3.5* 52.1 ± 4.8* 45.3 ± 3.9*
Pain VAS (mm) 70.1 ± 9.0 71.1 ± 8.7 59.8 ± 7.8† 55 ± 7.4† 56.7 ± 7.8‡ 53.5 ± 7.5‡ 51.3 ± 7.5* 44.1 ± 8.5* 41 ± 7.6* 36.3 ± 7.9* 40.5 ± 7.5* 33.1 ± 7.0* 39.3 ± 8.3* 29.8 ± 7.8*
Fatigue VAS (mm) 85.1 ± 4.6 83.8 ± 4.1 73 ± 4.5† 63.1 ± 4.3‡ 63.1 ± 4.7‡ 58.7 ± 5.1‡ 60.1 ± 4.4* 56.2 ± 5.5* 52.2 ± 4.0* 47.8 ± 4.7* 50.5 ± 3.8* 42.5 ± 4.1* 51.8 ± 4.5* 41.1 ± 4.2*
Dryness VAS (mm) 71.0 ± 8.3 72 ± 8.5 61.1 ± 8.3 55.3 ± 7.6‡ 58 ± 8.2† 52.2 ± 7.6‡ 56.3 ± 8.4‡ 44.1 ± 8.5* 53.8 ± 11.0* 36.3 ± 7.9* 51.8 ± 10.4* 30.7 ± 8.0* 51.8 ± 11.1* 25.1 ± 7.7*
Physician GA VAS
(mm)
89.7 ± 3.0 87.1 ± 2.3 78.6 ± 2.6† 69.1 ± 3.0† 73.1 ± 3.4‡ 65 ± 4.4‡ 65.0 ± 3.9* 56.6 ± 4.3* 56.6 ± 3.8* 50.3 ± 3.0* 54.7 ± 4.5* 45.8 ± 3.3* 56.1 ± 4.9* 44.0 ± 3.7*
Unstimulated salivary
flow (ml/minute)
0.08 ± 0.03 0.08 ± 0.04 0.1 ± 0.04 0.2 ± 0.04‡ 0.1 ± 0.04 0.3 ± 0.04‡ 0.1 ± 0.07 0.4 ± 0.02* 0.1 ± 0.06 0.3 ± 0.001* 0.1 ± 0.08 0.4 ± 0.04* 0.1 ± 0.08 0.4 ± 0.04*
Schirmer I test (mm/
5 minutes)
3.8 ± 0.6 3.8 ± 0.6 4 ± 0.5 5.5 ± 0.4‡ 4.5 ± 0.7 6.0 ± 0.5† 5.1 ± 0.8 6.3 ± 0.6‡ 5.1 ± 0.7 7.0 ± 0.7* 5.3 ± 0.7† 7.0 ± 0.7* 5.5 ± 0.8‡ 7.3 ± 0.8*
ESSDAI 19.8 ± 3.1 20.3 ± 2.9 17.6 ± 3.2 14.2a ± 2.8 14.2 ± 3.0‡ 9.8 ± 2.0‡ 12.3 ± 2.0* 9.4 ± 1.6‡ 10.2 ± 2.0* 5.7 ± 1.0* 9.7 ± 2.0* 5.7 ± 1.0* 8.8 ± 1.7* 5.2 ± 0.9*
Data presented as mean ± standard error of the mean. DMARD, disease-modifying anti-rheumatic drug; ESSDAI, EULAR Sjögren’s syndrome disease activity index; GA, global assessment; RTX, rituximab; VAS, visual















Figure 2 Clinical assessment in the rituximab and disease-modifying anti-rheumatic drug treatment groups. Clinical evaluation was
performed as follows: (A) global disease activity visual analogic scale (VAS), (B) pain VAS, (C) fatigue VAS, (D) dryness VAS, (E) physician global
assessment (GA) VAS, (F) unstimulated salivary flow, and (G)Schirmer I test. Bars in the line charts indicate mean ± standard error of the mean.
**P <0.01 and *P <0.05, comparison between the two treatment arms at the corresponding time point. DMARD, disease-modifying anti-rheumatic
drug; RTX, rituximab.
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http://arthritis-research.com/content/15/5/R172reduction of LTα and LTβ expression and these results
were not observed in patients treated with DMARDs. RTX
treatment was also able to interfere with the CXCR4/
CXCL12 and CXCR5/CXCL13 pathways. In particular, we
observed a consistent reduction of the assessed receptors
(CXCR4 and CXCR5) and a parallel increase of the corre-
sponding ligands (CXCL12 and CXCL13) (Figure 5C,D,E,F).
Conversely, no consistent modification in the expression
of such markers was observed after DMARD treatment.
Finally, neither RTX nor DMARD treatment led to a
modulation of BAFF expression (Figure 5G).
Discussion
To our knowledge, this is the first prospective, multi-
center, follow-up study performed in a large cohort of
active pSS patients, with recent disease onset for a
period of 120 weeks, to assess safety and efficacy of RTX
compared with DMARD treatment. Furthermore, we
evaluated both histological and molecular patterns in the
MSG tissue, induced by treatments.
One must point out that, in the last decades, therapeutic
approaches in pSS have been based on the use of agents
replacing the normal liquid secretion of the affected
glands and glucocorticoids and immunosuppressive agents
for extraglandular involvements. Available experimental
data and systematic reviews highlighted the limited evi-
dence for these drugs in pSS and the difficulties to suggest
solid therapeutic recommendations [26]. Consequently,
current therapeutic approaches are based on personal ex-
perience, expert opinion, and anecdotal studies, and until
now no drugs have been identified to reduce disease activ-
ity or prevent damage and complications.One limitation of this study is that the two treatment arms
took place in different centers, thus potentially introducing
bias. Despite the lack of a prospective randomization and
two different sites of enrolment, we provided data showing
that RTX treatment in patients affected by pSS is able to
significantly decrease the ESSDAI when compared with
the DMARD arm. Furthermore, this positive effect was
observed throughout the entire study period, independ-
ently of the value of disease activity. As far as the safety of
this treatment is concerned, RTX showed a good safety
profile and no patients discontinued treatment or experi-
enced side effects.
Depletion of B cells by RTX might reset immune toler-
ance and provide a new chance to an appropriate regula-
tion of autoreactive B cells [48]. Moreover, depleting B
cells might also influence the T-cell compartment, since
B cells are effective antigen-presenting cells and can lead
to autoantigen-specific >T-cell responses by providing
co-stimulatory signals and secretion of cytokines and
growth factors [49]. These data may partially explain the
therapeutic efficacy of RTX treatment in autoimmune
diseases [27].
Although few data are present in the literature to date,
evidence from both open-label studies and randomized
clinical trials provide the clue that RTX is effective in re-
ducing different disease manifestations of pSS patients,
such as sicca symptoms, extraglandular manifestations,
fatigue and improving saliva production and eventually
HR-QoL [28,30,31,36,38-40].
In our study, disease activity assessed by the ESSDAI
appeared to be significantly reduced from baseline, start-
ing from week 24 in both groups, but RTX was superior
Figure 3 Histological assessment of minor salivary gland biopsies. (A), (B) Histological scoring of minor salivary gland (MSG) biopsies in the
rituximab (RTX) and disease-modifying anti-rheumatic drug (DMARD) treatment groups at baseline and week 120. (C), (D) Percentage of CXCR4-
positive cells and CXCR5-positive cells inside the glandular infiltrate. Bars indicate mean ± standard error of the mean. ***P <0.001, **P <0.01 and
*P <0.05. (E) Percentage of patients displaying germinal centers (GCs) in the RTX and DMARD treatment groups at baseline and week 120. MNC,
mononuclear cells.
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partially due to a rapid and consistent score reduction of
constitutional, lymphadenopathy, glandular, articular and
cutaneous domains.
The second primary endpoint of this study was the
safety of RTX treatment in these patients, and our study
confirmed the safety profile of RTX therapy in pSS. No
patients in our cohort showed systemic or infusion-related
side effects and/or discontinued therapy. One must point
out that we followed our patients for a very long-term
period, performing six infusion courses in a period of
120 weeks. Furthermore, our patients did not develop any
humoral immunodeficiency related to repeated treatment
[50]. To our knowledge, no data are available in the litera-
ture concerning such a prolonged exposure to this drug in
early pSS patients.Concerning clinical assessment and secondary end-
points, we demonstrated a significant improvement of
the VAS global disease activity, VAS pain, VAS fatigue,
VAS dryness and VAS physician global assessment, when
compared with baseline, and such improvement was sig-
nificantly more pronounced in the RTX arm when com-
pared with the DMARD arm. To note, the superiority of
RTX was generally observed after two courses of therapy
and continued throughout the study period. Concerning
dryness, the RTX treatment group progressively im-
proved from week 12 until the end of the study; on the
contrary, in the DMARD treatment group we observed a
slight improvement from week 12 that plateaued for the
following period, and these data were confirmed by vali-
dated measures of salivary and lacrimal gland function.
When we searched for a correlation between the extent of
Figure 4 Histological analysis of minor salivary gland biopsies in the rituximab and disease-modifying anti-rheumatic drug treatment
groups. Histological analysis of minor salivary gland (MSG) biopsies in the rituximab (RTX) and disease-modifying anti-rheumatic drug (DMARD)
treatment groups at baseline and week 120. 4×, 10×, 20× and 40×, level of magnification of the corresponding picture H&E, hematoxylin–eosin.
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and focus score, on one hand, and the clinical response,
valuated by clinimetric tests, on the other, we did not find
any significant correlation. Identification of potentially
helpful biomarkers has been one of the main goals of the
last two decades in autoimmunity, but the sample size of
this study calculated to the assessed endpoints was unable
to identify significant correlations.
Previous available studies in short series of pSS patients
showed that beneficial effects occurred between 12 and
24 weeks after treatment and paralleled B-cell depletion in
peripheral blood. Circulating CD19+ B cells started to re-
populate at week 24, and 36 to 48 weeks after treatment
were partially or fully reconstituted [32,40,51], describing
only transient therapeutic effects, probably related to the
relapse of the disease following B-cell repopulation. Wespeculate that the infusion regimen every 24 weeks pre-
vented our patients developing disease flares secondary to
the B-cell reconstitution. On these bases, RTX infusions
(1,000 mg twice with an interval of 2 weeks) every
24 weeks in combination with long-term steroids might
be a better strategy when compared with an on-demand
regimen. Taken together, our data confirm that patients
with early, active disease with extraglandular manifesta-
tions are likely to benefit from RTX treatment.
According to the aims of our study, we investigated
whether, besides clinical efficacy, different systemic treat-
ment may also change the extent of glandular involve-
ment at baseline and week 120. We did not observe any
statistically significant reduction in Chisholm and Mason
score, focus score and GC presence in MSGs of patients
treated with DMARDs. On the contrary, we observed that
Figure 5 Molecular analysis of minor salivary gland biopsies in the rituximab and disease-modifying anti-rheumatic drug treatment
groups. Relative mRNA quantification of (A) LTα, (B) LTβ, (C) CXCR4, (D) CXCL12, (E) CXCR5, (F) CXCL13, and (G) B-cell activating factor (BAFF)
was assessed by quantitative real-time polymerase chain reaction in salivary glands obtained from 41 pSS patients and five healthy donors (HD).
Bars indicate mean ± standard error of the mean. Levels are expressed as the fold increase or decrease in pSS MSGs compared with HD MSGs.
***P <0.001; **P <0.01 and *P <0.05. DMARD, disease-modifying anti-rheumatic drug; LT, lymphotoxin; RTX, rituximab.
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patients after 120 weeks of treatment, thereby supporting
the possibility to reverse from a FLS to a nonspecific
chronic sialadenitis pattern or a full restoration of MSG
architecture in these early patients. Furthermore we
also observed that the number of GC-positive biopsies
dropped from 52.6 to 5.2% in RTX-treated patients,
and at the end of the study only one out of 19 patients still
displayed GCs after RTX treatment. We might thus
hypothesize that RTX is able to reduce glandular infiltrate
and interfere with B-cell/T-cell compartmentalization, and
consequently with the formation of ectopic lymphoid
structures and GC-like structures in pSS MSGs.
In line with these data, we also observed a reduction
of CXCR4-positive and CXCR5-positive cell percentage
in total infiltrating mononuclear cells in RTX-treated
but not in DMARD-treated patients at week 120 when
compared with baseline. CXCR5 is expressed by naïve B
cells, activated B cells, GC B cells, follicular B cells, follicu-
lar T cells, and CD4+ T cells, whereas CXCR4 is expressed
on naïve B cells, memory B cells, GC B cells (mainly cen-
troblasts), plasmablasts and plasma cells [52]. Their reduc-
tion might be partially due to the disappearance of B cells
from MSGs and the reduction of inflammatory infiltrate.
This reduction in the number of CXCR4-positive cells
and CXCR5-positive cells was confirmed by the paral-
lel reduction of CXCR4 and CXCR5 mRNA in MSGs
of the RTX arm.
Furthermore, we found a statistically significant increase
of CXCL12 and CXCL13 mRNA levels in the RTX arm,
when compared with both baseline and the DMARD arm,at week 120. Thus, in this setting, we observed a consistent
reduction of receptors (CXCR4 and CXCR5) and a parallel
increase of corresponding ligands (CXCL12 and CXCL13).
CXCL13, also known as B-lymphocyte chemoattractant-1,
is produced by macrophages, T cells, and stromal, endothe-
lial and ductal epithelial cells, and is present at very low
levels in normal MSG biopsies [18,21]. CXCL13 is in-
volved in the starting events leading to lymphoid organ
formation and, mice lacking CXCL13 and its receptor
CXCR5 show a partial blockade of lymph node organo-
genesis [53]. CXCL13 production is sustained by follicular
dendritic cells, which play a pivotal role in the affinity
maturation and antigenic selection of B cells within the
GC. Furthermore, CXCL13 mainly drives GC B cells to
the light zone where antigen selection occurs, and higher
degree of lymphoid organization was found to be associ-
ated with an increased expression of this molecule [5].
CXCL12, or stromal cell-derived factor-1, is present in
ductal epithelial cells and unlike CXCL13 was also found
in MSG biopsies of healthy subjects. Concerning lymph-
oid structures, CXCL12 is present in the dark zone of
GCs and, to note, was mainly associated with malig-
nant CD20+ marginal zone-like B cells [54]. The che-
mokine–chemokine receptor pairs CXCL13–CXCR5 and
CXCL12–CXCR4 might thus be closely associated with
development of ectopic GC-like structures [5,21-23] as
well as the peripheral B-cell abnormalities in pSS [25].
Increased levels of LTα and LTβmolecules, and their ac-
tivation, have been associated with the presence of ectopic
lymphoid structures at sites of chronic inflammation in
several autoimmune diseases [20]. After treatment we
Carubbi et al. Arthritis Research & Therapy 2013, 15:R172 Page 12 of 14
http://arthritis-research.com/content/15/5/R172observed that LTα and LTβ levels were significantly re-
duced at mRNA level in the RTX arm when compared
with both baseline and the DMARD arm, and their
amounts mirrored the values observed in healthy donor
MSGs.
Taking together our molecular results, we might
hypothesize that RTX treatment is able to deplete B
cells in MSGs of pSS patients, but despite the observed re-
duction of inflammatory infiltrate, mainly B cells, and a
disappearance of ectopic lymphoid structures, including a
reduction of LTα and LTβ levels after RTX treatment, an
abnormal micro-environment favoring B-cell homing in
MSGs seems to persist.
This hypothesis is further supported by the observa-
tion that neither RTX or DMARD treatment led to a
modulation of BAFF expression, which remains at the
same level as at baseline. It is conceivable that, despite
B-cell depletion, BAFF is not affected by any of these
compounds. Several reports showed that BAFF in saliv-
ary glands appears to be produced not only by infiltrat-
ing B cells but also by T cells and ductal epithelial cells
[55], primed by viruses, via the type 1 interferon path-
way and/or viral Toll-like receptor ligands [56,57].
The formation of tertiary lymphoid tissue is the result
of a multi-step dynamic process involving immune cells,
epithelial cells, high endothelial venules, chemokines,
cytokines, growth factors and related receptors. To our
knowledge, RTX treatment seems to be able to interfere
with this process, not only depleting B cells but also tun-
ing the delicate equilibrium between cells, molecules
and receptors, partially affecting the pro-B-cell inflam-
matory milieu. In our study we provided, for the first
time, evidence regarding the modulation, after RTX
treatment, of ectopic expression of lymphotoxins and
homeostatic chemokines such as CXCL13 and CXCL12
and the interaction with their receptors, CXCR5 and
CXCR4 respectively.
Conclusion
This paper reports the first prospective, multi-center,
follow-up study performed in a large cohort of active
pSS patients, with recent disease onset carried out for a
period of 120 weeks, to assess safety and efficacy of RTX
compared with DMARD treatment, and correlating the
clinical response to the immune-histological and mo-
lecular patterns before and after treatments. Our study
shows that B-cell depleting therapy by RTX offers a
promising and safe treatment for these patients, signifi-
cantly ameliorating clinical features, when compared
with other therapies, and restoring B-cell disturbance, by
reducing immune infiltrate and lymphoid organization
in target tissues. In fact, this therapy is able to interfere
with the formation of tertiary lymphoid tissue, not only
depleting B cells but also tuning the delicate equilibriumbetween cells, molecules and receptors, partially affect-
ing the pro-B-cell inflammatory milieu that is typical of the
inflamed glands. To our knowledge this study provided, for
the first time, evidence regarding the modulation, after
RTX treatment, of ectopic expression of lymphotoxins and
homeostatic chemokines such as CXCL13 and CXCL12
and the interaction with their receptors, CXCR5 and
CXCR4 respectively. Further studies are in progress to
overcome some limitations of this study, such as the small
number of patients studied in each group and the lack of
randomization, on one hand, and additional biomolecular
information from using gene array techniques on the
other.
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